Home/ Stocks/ OSTX

OS Therapies Incorporated

OSTX XASE

$1.66 -0.04 (-2.35%) ▼ 15-min delayed

Open

$1.71

High

$1.72

Low

$1.66

Volume

300.0K

Market Cap

$69.78M

About OS Therapies Incorporated

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 5 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	N/A	$-28,753,844	$-0.98
FY 2025	N/A	$-28,753,844	$-0.98
Q3 2025	N/A	$-6,879,530	$-0.21
Q2 2025	N/A	$-4,536,622	$-0.19

Related Market News

No specific coverage for OSTX yet. Check out our latest market news or earnings calendar.

Get OSTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on OS Therapies Incorporated.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.